Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.9, 2013-06, pp. : 1151-1160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging treatments for irritable bowel syndrome

By Ahn Joseph Ehrenpreis Eli D

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 1, 2002-01 ,pp. : 9-21

Informa Healthcare

Access to resources Recommend Favorite

Lubiprostone: In Constipation-Predominant Irritable Bowel Syndrome

By Carter Natalie J. Scott Lesley J.

Drugs, Vol. 69, Iss. 9, 2009-06 ,pp. : 1229-1237

Adis International

Access to resources Recommend Favorite

Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome

Mini Reviews in Medicinal Chemistry, Vol. 16, Iss. 18, 2016-12 ,pp. : 1462-1469

Bentham Science Publishers

Access to resources Recommend Favorite

Crofelemer is promising for the treatment for patients with diarrhoea-predominant irritable bowel syndrome

Inpharma, Vol. 1, Iss. 1590, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome

Current Pharmaceutical Design, Vol. 16, Iss. 33, 2010-11 ,pp. : 3638-3645

Bentham Science Publishers

Access to resources Recommend Favorite